One or Two Immune Checkpoint Inhibitors?
CANCER CELL (2019)
作者
我是这篇论文的作者
推荐
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
Kevin J. Harrington, Barbara Burtness, Richard Greil, Denis Soulieres, Makoto Tahara, Gilberto de Castro Jr, Amanda Psyrri, Irene Brana, Neus Baste, Prakash Neupane, Ase Bratland, Thorsten Fuereder, Brett G. M. Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Jianxin Lin, Burak Gumuscu, Ramona F. Swaby, Danny Rischin
JOURNAL OF CLINICAL ONCOLOGY (2023)
Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
Liwei Sun, Xuelong Xu, Fanguang Meng, Qian Liu, Hankang Wang, Xiaodong Li, Guijie Li, Feng Chen
FRONTIERS IN ONCOLOGY (2022)
The performance and perspectives of dendritic cell vaccines modified by immune checkpoint inhibitors or stimulants
Jiage Ding, Yanyan Zheng, Gang Wang, Junnian Zheng, Dafei Chai
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2022)
The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
Patrizia Leone, Antonio Giovanni Solimando, Rossella Fasano, Antonella Argentiero, Eleonora Malerba, Alessio Buonavoglia, Luigi Giovanni Lupo, Valli De Re, Nicola Silvestris, Vito Racanelli
VACCINES (2021)
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
Faisal Fa'ak, Maryam Buni, Adewunmi Falohun, Huifang Lu, Juhee Song, Daniel H. Johnson, Chrystia M. Zobniw, Van A. Trinh, Muhammad Osama Awiwi, Nourel Hoda Tahon, Khaled M. Elsayes, Kaysia Ludford, Emma J. Montazari, Julia Chernis, Maya Dimitrova, Sabina Sandigursky, Jeffrey A. Sparks, Osama Abu-Shawer, Osama Rahma, Uma Thanarajasingam, Ashley M. Zeman, Rafee Talukder, Namrata Singh, Sarah H. Chung, Petros Grivas, May Daher, Ala Abudayyeh, Iman Osman, Jeffrey Weber, Jean H. Tayar, Maria E. Suarez-Almazor, Noha Abdel-Wahab, Adi Diab
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)
First-line chemotherapy or in combination with programmed cell death protein-1 antibody in patients with metastatic or recurrent biliary tract cancer
Shu Zhao, Xue-Guang Guo, Dong Zhang, Gang Zhou, Peng Song, Jing Yang, Yong Zhang, Peng Li, Yi Hu, Peng Wang
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)
Hot or cold: Bioengineering immune contextures into in vitro patient-derived tumor models
Nathaniel Sheng Hua Too, Nicholas Ching Wei Ho, Christabella Adine, N. Gopalakrishna Iyer, Eliza Li Shan Fong
ADVANCED DRUG DELIVERY REVIEWS (2021)
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
Rom Leidner, Kevin Conlon, Douglas G. Mcneel, Andrea Wang-Gillam, Sumati Gupta, Robert Wesolowski, Monica Chaudhari, Nadia Hassounah, Jong Bong Lee, Lang Ho Lee, Jessica A. O'Keeffe, Nancy Lewis, George N. Pavlakis, John A. Thompson
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)
Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors
Patrick T. Magahis, Steven B. Maron, Darren Cowzer, Stephanie King, Mark Schattner, Yelena Janjigian, David Faleck, Monika Laszkowska
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)
Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors
Anusha S. Thomas, Weijie Ma, Yinghong Wang
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy of Immune Checkpoint Inhibitors against Advanced or Metastatic Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
Eun-Joo Park, Hyo-Jung Park, Kyung-Won Kim, Chong-Hyun Suh, Changhoon Yoo, Young-Kwang Chae, Sree Harsha Tirumani, Nikhil H. Ramaiya
CANCERS (2022)
Immune Checkpoint Inhibitors in People Living with HIV/AIDS: Facts and Controversies
Valeria Castelli, Andrea Lombardi, Emanuele Palomba, Giorgio Bozzi, Riccardo Ungaro, Laura Alagna, Davide Mangioni, Antonio Muscatello, Alessandra Bandera, Andrea Gori
CELLS (2021)
Multisystem immune-related adverse events due to toripalimab: Two cases-based review
Yanran Chen, Yulan Chen, Jingyi Xie, Dongzhou Liu, Xiaoping Hong
FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)
Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients
Yiqing Huang, Yu Yang Soon, Folefac Aminkeng, Sen Hee Tay, Yvonne Ang, Adrian C. L. Kee, Boon Cher Goh, Alvin S. C. Wong, Ross A. Soo
INTERNATIONAL JOURNAL OF CANCER (2022)
The gut microbiome and efficacy of cancer immunotherapy
Giandomenico Roviello, Luigi Francesco Iannone, Melissa Bersanelli, Enrico Mini, Martina Catalano
PHARMACOLOGY & THERAPEUTICS (2022)
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS) (vol 152, pg 116, 2021)
Helen Gogas, Reinhard Dummer, Paolo A. Ascierto, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Vanna Chiarion Sileni, Caroline Dutriaux, Naoya Yamazaki, Carmen Loquai, Paola Queirolo, Groot J. de Willem, Abir T. Sellier, Jeanne Suissa, Juliette Murris, Ashwin Gollerkeri, Caroline Robert, Keith T. Flaherty
EUROPEAN JOURNAL OF CANCER (2022)
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial COMBI-i)
Hussein A. Tawbi, Caroline Robert, Jan C. Brase, Daniel Gusenleitner, Eduard Gasal, James Garrett, Alexander Savchenko, Gullu Gorgun, Keith T. Flaherty, Antoni Ribas, Reinhard Dummer, Dirk Schadendorf, Georgina Long, Paul D. Nathan, Paolo A. Ascierto
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle
Sami Antoun, Emilie Lanoy, Samy Ammari, Siham Farhane, Lisa Martin, Caroline Robert, David Planchard, Emilie Routier, Anne Laure Voisin, Sabine Messayke, Stephane Champiat, Jean Marie Michot, Salim Laghouati, Olivier Lambotte, Aurelien Marabelle, Vickie Baracos
EUROPEAN JOURNAL OF CANCER (2023)
Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors
Franck Carbonnel, Emilie Routier, Thierry Lazure, Charlotte Mussini, Christophe Bellanger, Carine Merklen, Bakhtiar Bejou, Anthony Buisson, Aurelien Amiot, Antoine Meyer, Catherine Dong, Caroline Robert
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)
Phase I Study of Androgen Deprivation Therapy in Combination with Anti-PD-1 in Melanoma Patients Pretreated with Anti-PD-1
Caroline Robert, Celeste Lebbe, Thierry Lesimple, Eija Lundstrom, Valerie Nicolas, Bruno Gavillet, Philippa Crompton, Barouyr Baroudjian, Emilie Routier, Ferdy J. Lejeune
CLINICAL CANCER RESEARCH (2023)
Post-transcriptional polyadenylation site cleavage maintains 3' -end processing upon DNA damage
Rym Sfaxi, Biswendu Biswas, Galina Boldina, Mandy Cadix, Nicolas Servant, Huimin Chen, Daniel R. Larson, Martin Dutertre, Caroline Robert, Stephan Vagner
EMBO JOURNAL (2023)
Tenofovir-induced osteoporosis fracture in a patient using PrEP: A pitfall for the oncologist
Marie Boileau, Emilie Routier, Arnaud Pouvelle, Olivier Lambotte, Caroline Robert
EUROPEAN JOURNAL OF CANCER (2023)
Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma
Julia Lai-Kwon, Sarah Jacques, Matteo Carlino, Naima Benannoune, Caroline Robert, Clara Allayous, Barouyr Baroudjian, Celeste Lebbe, Lisa Zimmer, Zeynep Eroglu, Turkan Ozturk Topcu, Florentia Dimitriou, Andrew Haydon, Serigne N. Lo, Alexander M. Menzies, Georgina Long
EUROPEAN JOURNAL OF CANCER (2023)
eIF4F translation initiation complex, a predictive marker of response to immunotherapy in mucosal melanoma
Antoine Moya-Plana, Carine Ngo, Emilie Lanoy, Stephan Vagner, Caroline Robert
EUROPEAN JOURNAL OF CANCER (2023)
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
Caroline Robert, Matteo S. Carlino, Catriona Mcneil, Antoni Ribas, Jean-Jacques Grob, Jacob Schachter, Marta Nyakas, Damien Kee, Teresa M. Petrella, Arnold Blaustein, Michal Lotem, Ana Arance, Adil I. Daud, Omid Hamid, James Larkin, James Anderson, Clemens Krepler, Dmitri Grebennik, Georgina V. Long
JOURNAL OF CLINICAL ONCOLOGY (2023)
Cured or Not? Long-term Outcomes of Immunotherapy Responders. Focus on Melanoma
Celine Boutros, Djaouida Belkadi-Sadou, Antoine Marchand, Severine Roy, Emilie Routier, Caroline Robert
CURRENT ONCOLOGY REPORTS (2023)
Genomic mutation landscape of skin cancers from DNA repair-deficient xeroderma pigmentosum patients
Andrey A. Yurchenko, Fatemeh Rajabi, Tirzah Braz-Petta, Hiva Fassihi, Alan Lehmann, Chikako Nishigori, Jinxin Wang, Ismael Padioleau, Konstantin Gunbin, Leonardo Panunzi, Fanny Morice-Picard, Pierre Laplante, Caroline Robert, Patricia L. Kannouche, Carlos F. M. Menck, Alain Sarasin, Sergey I. Nikolaev
NATURE COMMUNICATIONS (2023)
Drug-tolerant persister cells in cancer: the cutting edges and future directions
Yi Pu, Lu Li, Haoning Peng, Lunxu Liu, Dominique Heymann, Caroline Robert, Francois Vallette, Shensi Shen
NATURE REVIEWS CLINICAL ONCOLOGY (2023)